SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

SCHEDULE OF PURCHASE PRICE AND PRELIMINARY PURCHASE PRICE ALLOCATIONS

The following table summarizes the purchase price and preliminary purchase price allocations relating to the acquisition:

Cash	$	2,500,000
Common Stock		1,000,000
Total purchase consideration	$	3,500,000
Assets
Net working capital (including cash)	$	912,000
Property and equipment		326,000
Other assets		8,000
Customer relationships		700,000
Trade names and trademarks		150,000
Goodwill		1,404,000
Total net assets	$	3,500,000

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following potentially dilutive securities have been excluded from the computations of weighted average shares of Common Stock outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive:

	As of December 31,
	2023		2022
Shares underlying options outstanding		683,695		806,392
Shares underlying warrants outstanding		4,649,952		4,649,952
Anti-dilutive securities		5,333,647		5,456,344

SCHEDULE OF REVENUE RECOGNITION

	As of December 31,
	2023		2022
Patient service fees1	$	2,199,558	$	—
Histology service fees		272,660		—
Medical director fees		19,324		—
Department of Defense observational studies		19,442		—
Other revenues2		21,515		4,803
Total net revenue	$	2,532,499	$	4,803

¹ Patient services fees includes direct billing for CyPath® Lung diagnostic test.

² Other revenues include pre-acquisition CyPath® Lung royalty income and laboratory services.

SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE

Property and equipment are carried at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the asset. Amortization of leasehold improvements is computed using the shorter of the lease term or estimated useful life of the asset. Additions and improvements are capitalized, while repairs and maintenance are expensed as incurred. Useful lives of each asset class are as follows:

Asset Category	Useful Life
Computer equipment	3-5 years
Computer software	3 years
Equipment	3-5 years
Furniture and fixtures	5-7 years
Vehicles	5 years
Leasehold improvements	Lesser of lease term or useful life

SCHEDULE OF INTANGIBLE ASSETS ADJUSTMENTS

Intangible assets, net of accumulated amortization, are summarized as follows as of December 31, 2023:

Description	Date Acquired	Useful Life	Cost		Amortization			Net
Goodwill	9/18/2023		$	1,404,486	$	—		$	1,404,486
Trade names and trademarks	9/18/2023	18 years		150,000		(2,361	)		147,639
Customer relationships	9/18/2023	14 years		700,000		(14,167	)		685,833
Total Intangible Assets			$	2,254,486	$	(16,528	)	$	2,237,958

SCHEDULE OF SEGMENT INFORMATION

	As of December 31,
	2023			2022
Net revenues:
Diagnostic R&D	$	19,442		$	—
Laboratory services		2,513,057			4,803
Total net revenues		2,532,499			4,803
Operating expenses:
Diagnostic R&D		(1,724,597	)		(1,524,170	)
Laboratory services		(3,769,783	)		(95,041	)
General corporate activities		(5,011,347	)		(2,396,650	)
Total operating loss		(7,973,228	)		(4,011,058	)
Non-operating income (expense), net		57,210			(4,140,596	)
Net loss before income taxes		(7,916,018	)		(8,151,654	)
Income tax expense		(20,993	)		(2,459	)
Net Loss	$	(7,937,011	)	$	(8,154,113	)